JP2006518726A - G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 - Google Patents
G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 Download PDFInfo
- Publication number
- JP2006518726A JP2006518726A JP2006502131A JP2006502131A JP2006518726A JP 2006518726 A JP2006518726 A JP 2006518726A JP 2006502131 A JP2006502131 A JP 2006502131A JP 2006502131 A JP2006502131 A JP 2006502131A JP 2006518726 A JP2006518726 A JP 2006518726A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- formula
- methylquinolinio
- amido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FJSBIJBRWDYVBW-VEMPYYTQSA-O C/C(/NC(c1cccc(C(N/C(/C=[NH+]/C)=C/c2ccccc2)=O)n1)=O)=C\c1ccccc1NC Chemical compound C/C(/NC(c1cccc(C(N/C(/C=[NH+]/C)=C/c2ccccc2)=O)n1)=O)=C\c1ccccc1NC FJSBIJBRWDYVBW-VEMPYYTQSA-O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0301478A FR2850970B1 (fr) | 2003-02-07 | 2003-02-07 | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
| PCT/FR2004/000260 WO2004072027A2 (fr) | 2003-02-07 | 2004-02-05 | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006518726A true JP2006518726A (ja) | 2006-08-17 |
| JP2006518726A5 JP2006518726A5 (cg-RX-API-DMAC7.html) | 2007-04-05 |
Family
ID=32731875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502131A Pending JP2006518726A (ja) | 2003-02-07 | 2004-02-05 | G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1603898A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006518726A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004210753A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0407320A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2514105A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2850970B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05007648A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004072027A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101357B2 (en) | 2009-04-09 | 2012-01-24 | Panasonic Corporation | Method for inhibiting telomerase reaction using an anionic phthalocyanine compound |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887873B2 (en) | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
| US8293716B2 (en) | 2005-05-26 | 2012-10-23 | Ramot At Tel Aviv University Ltd. | Method of treating cancer by modulation of mortalin |
| EP2061464A2 (en) * | 2006-09-14 | 2009-05-27 | Ramot, at Tel Aviv University Ltd. | Combination therapy for tumoral disease treatment |
| GB0706932D0 (en) * | 2007-04-10 | 2007-05-16 | Univ London Pharmacy | Ureylene derivatives |
| WO2009040819A2 (en) | 2007-09-25 | 2009-04-02 | Ramot At Tel Aviv University Ltd. | DOWN-REGULATION OF MORTALIN BY siRNA |
| JP4410844B1 (ja) | 2008-05-27 | 2010-02-03 | パナソニック株式会社 | G−quadruplex検出方法、G−quadruplex形成DNA検出方法およびテロメラーゼ活性測定方法 |
| CN108066340B (zh) * | 2016-11-10 | 2020-10-27 | 中国科学院化学研究所 | 药物组合物 |
| CN108066341B (zh) * | 2016-11-10 | 2020-10-30 | 中国科学院化学研究所 | 化合物在制备抗癌药物中的用途 |
| WO2018211148A1 (en) * | 2017-05-19 | 2018-11-22 | Universite De Bretagne Occidentale | Bisquinolium derivatives for preventing or treating ebv-related cancers |
| CN113272294A (zh) * | 2018-08-24 | 2021-08-17 | 雅典学院生物医学研究基金会 | 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001040218A1 (fr) * | 1999-11-29 | 2001-06-07 | Aventis Pharma S.A. | Derives arylamines et leur application comme agent antitelomerase |
| WO2002055515A1 (fr) * | 2001-01-09 | 2002-07-18 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
| WO2002076975A1 (fr) * | 2001-03-23 | 2002-10-03 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
| WO2002096903A2 (fr) * | 2001-05-28 | 2002-12-05 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2821355A1 (fr) * | 2001-02-23 | 2002-08-30 | Aventis Pharma Sa | Derives chimiques et leur application comme agent antitelomerase |
-
2003
- 2003-02-07 FR FR0301478A patent/FR2850970B1/fr not_active Expired - Fee Related
-
2004
- 2004-02-05 WO PCT/FR2004/000260 patent/WO2004072027A2/fr not_active Ceased
- 2004-02-05 MX MXPA05007648A patent/MXPA05007648A/es not_active Application Discontinuation
- 2004-02-05 BR BRPI0407320-7A patent/BRPI0407320A/pt not_active IP Right Cessation
- 2004-02-05 JP JP2006502131A patent/JP2006518726A/ja active Pending
- 2004-02-05 EP EP04708378A patent/EP1603898A2/fr not_active Withdrawn
- 2004-02-05 AU AU2004210753A patent/AU2004210753A1/en not_active Abandoned
- 2004-02-05 CA CA002514105A patent/CA2514105A1/fr not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001040218A1 (fr) * | 1999-11-29 | 2001-06-07 | Aventis Pharma S.A. | Derives arylamines et leur application comme agent antitelomerase |
| WO2002055515A1 (fr) * | 2001-01-09 | 2002-07-18 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
| WO2002076975A1 (fr) * | 2001-03-23 | 2002-10-03 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
| WO2002096903A2 (fr) * | 2001-05-28 | 2002-12-05 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101357B2 (en) | 2009-04-09 | 2012-01-24 | Panasonic Corporation | Method for inhibiting telomerase reaction using an anionic phthalocyanine compound |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0407320A (pt) | 2006-02-21 |
| FR2850970B1 (fr) | 2006-07-07 |
| EP1603898A2 (fr) | 2005-12-14 |
| MXPA05007648A (es) | 2006-12-15 |
| WO2004072027A3 (fr) | 2004-09-23 |
| WO2004072027A2 (fr) | 2004-08-26 |
| AU2004210753A1 (en) | 2004-08-26 |
| CA2514105A1 (fr) | 2004-08-26 |
| FR2850970A1 (fr) | 2004-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6047556B2 (ja) | Lrrk2キナーゼ活性の阻害剤 | |
| JP7320263B2 (ja) | Ezh2阻害剤及びその使用 | |
| US20220227729A1 (en) | Identification and use of kras inhibitors | |
| JP7320823B2 (ja) | プテリジノン誘導体のegfr阻害剤としての使用 | |
| US8124649B2 (en) | Oxindole compounds | |
| CN117730075A (zh) | 一种吡唑衍生物,其制备方法和在药学上的应用 | |
| KR20160076519A (ko) | Kras g12c 억제제 | |
| RU2763328C2 (ru) | Кристаллический ингибитор fgfr4 и его применение | |
| BR112016030697B1 (pt) | Compostos inibidores de desmetilase-1 lisina-específica, composição farmacêutica e seus usos | |
| CN107567445B (zh) | 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2-苯基-3h-咪唑并[4,5-b]吡啶衍生物 | |
| JP2022526220A (ja) | 選択的なcdk12/13阻害剤としての置換された5-シクロプロピル-1h-ピラゾール-3-イル-アミン誘導体 | |
| WO2011153942A1 (zh) | 氰基喹啉衍生物 | |
| KR20170018084A (ko) | Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 | |
| JP2004534046A (ja) | 化学誘導体および抗テロメラーゼ剤としてのその使用 | |
| CA3194868A1 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| ES2972862T3 (es) | Compuestos de pirropirimidina como inhibidores de MNK | |
| WO2011127406A2 (en) | Acridines as inhibitors of haspin and dyrk kinases | |
| AU2004210753A1 (en) | Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent | |
| EP4460492A1 (en) | Compounds containing a hydroxyphenyl moiety and their use | |
| US20070232572A1 (en) | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent | |
| EP3556756B1 (en) | Substituted propanamides as inhibitors of nucleases | |
| EP3632912B1 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| WO2017192228A1 (en) | Pak1 inhibitors and uses thereof | |
| WO2026105155A1 (en) | Tricyclic compound for breast and ovarian cancer treatment | |
| CA2721595A1 (en) | Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide andmethods of use therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100824 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110208 |